Columbia Science Review
  • Home
  • About
    • Executive Board
    • Editorial Board
  • Blog
  • Events
    • 2022-2023
    • 2021-2022
    • 2020-2021
    • 2019-2020
    • 2018-2019
    • 2017-2018
    • 2016-2017
  • Publications
  • COVID-19 Public Hub
    • Interviews >
      • Biology of COVID-19
      • Public Health
      • Technology & Data
    • Frontline Stories >
      • Healthcare Workers
      • Global Health
      • Volunteer Efforts
    • Resources & Links >
      • FAQ's
      • Resource Hubs
      • Student Opportunities
      • Podcasts & Graphics
      • Mental Health Resources
      • Twitter Feeds
      • BLM Resources
    • Columbia Events >
      • Campus Events
      • CUMC COVID-19 Symposium
      • CSR Events
    • Our Team
  • Contact

The Power of Peptides: Tat-beclin 1

2/13/2013

1 Comment

 
Picture
By Ian MacArthur

A new synthetic peptide may hold the key to curing some of mankind’s most tenacious illnesses. Researchers at the University of Texas Southwestern Medical Center led by Dr. Beth Levine recently synthesized Tat-beclin 1, a molecule that shows promise as a means of developing treatments against cancer, infectious disease, and degenerative neurological disorders.

Peptides differ from proteins on the basis of size. Although both are comprised of amino acid chains, peptides are classified as chains numbering 50 or fewer amino acids. Tat-beclin 1 is a 31 amino acid peptide whose demonstrated therapeutic value lies in its ability to induce the cellular process of autophagy.
​
Autophagy is the process by which cells recycle valuable components of large biological molecules to be reused in the synthesis of new molecules. Enzymes help to degrade unused compounds within the cell and then aid in constructing new compounds from the individual recycled components.  The process is essential for the maintenance of cellular health as well as the ability of cells to combat various diseases.

To study the effects of the peptide on disease resistance, Dr. Levine’s team treated mice with Tat-beclin 1 before infecting them with the West Nile virus and the insect-borne illness chikungunya. The mice treated with the peptide demonstrated increased resistance to such illnesses. Additionally, the team reported that human cells treated with Tat-beclin 1 in vitro were resistant to HIV. The effectiveness of the peptide against HIV in vivo remains to be tested.
The Levine group derived the amino acid sequence for Tat-beclin 1 from beclin 1, a protein previously identified by Dr. Levine to be crucial in autophagy. Subsequent research has identified defects in beclin 1 to underlie many types of diseases, and corroborated the importance of autophagy in defending the body against cancer.

The disruption of autophagy has been linked to a variety of human health conditions. Besides the onset of infectious disease, autophagy inhibition has been demonstrated to play a role in aging, breast, lung, and ovarian cancer, and degenerative neurological conditions such as Parkinson’s and Alzheimer’s. Thus, the potential for Tat-beclin 1 to be developed into therapeutic agents to combat these maladies is immense.

In studies of the effects of beclin 1 expression on Parkinson’s and Lewy body disease, researchers indicated that heightened beclin 1 levels coincided with the degradation of α-synuclein, the protein whose cellular buildup is closely associated with these disorders. It stands to reason, then, that the use of Tat-beclin 1 as a stand-in for heightened beclin 1 expression might yield a similar result.
​
Although the initial laboratory results of Tat-beclin 1 have yet to be reproduced on a clinical scale, the initial success of the peptide will surely precipitate a host of new drugs that may undergo testing in clinical trials. It is still too early to say whether or not Tat-belclin 1 truly holds the key to health, but the lessons learned from the peptide and its significance in autophagy will surely prove invaluable in future thinking about the treatment of illness.

1 Comment
Taylor Hicken link
1/17/2021 07:19:57 pm

I appreciated it when you shared that the difference between peptides and protein is their sizes. This ingredient has been proven to help treat tenacious diseases that can be fatal to human beings. I would like to think if a company is planning to develop a product that contains peptides, it should consider getting the research one from a reliable supplier.

Reply



Leave a Reply.

    Categories

    All
    Artificial Intelligence
    Halloween 2022

    Archives

    November 2022
    October 2022
    June 2022
    January 2022
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    November 2019
    October 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    April 2018
    March 2018
    February 2018
    November 2017
    October 2017
    May 2017
    April 2017
    April 2016
    March 2016
    February 2016
    December 2015
    November 2015
    October 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    May 2014
    April 2014
    March 2014
    February 2014
    December 2013
    November 2013
    October 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    April 2011
    March 2011
    February 2011
    September 2010
    August 2010
    July 2010
    June 2010
    May 2010
    April 2010
    March 2010
    February 2010
    January 2010
    December 2009
    November 2009
    July 2009
    May 2009

Columbia Science Review
© COPYRIGHT 2022. ALL RIGHTS RESERVED.
Photos used under Creative Commons from driver Photographer, BrevisPhotography, digitalbob8, Rennett Stowe, Kristine Paulus
  • Home
  • About
    • Executive Board
    • Editorial Board
  • Blog
  • Events
    • 2022-2023
    • 2021-2022
    • 2020-2021
    • 2019-2020
    • 2018-2019
    • 2017-2018
    • 2016-2017
  • Publications
  • COVID-19 Public Hub
    • Interviews >
      • Biology of COVID-19
      • Public Health
      • Technology & Data
    • Frontline Stories >
      • Healthcare Workers
      • Global Health
      • Volunteer Efforts
    • Resources & Links >
      • FAQ's
      • Resource Hubs
      • Student Opportunities
      • Podcasts & Graphics
      • Mental Health Resources
      • Twitter Feeds
      • BLM Resources
    • Columbia Events >
      • Campus Events
      • CUMC COVID-19 Symposium
      • CSR Events
    • Our Team
  • Contact